INS and Hypoglycemia: These observations are consistent with those for patients treated with GLP-1 RAs in combination with metformin and/or thiazolidinediones in that addition of exenatide BID to a treatment regimen without insulin-secretagogues is not associated with an increased risk of hypoglycaemia 18,19,21.